@daleinquint.bsky.social
Reposted
Suppressing APOBEC enzymes—key drivers of tumor mutations—could dramatically delay drug resistance in non-small cell #lungcancer (#NSCLC), up to 1200%!
Targeting the generation of variation may be the best route to personalized and durable treatments 🧪.
ysph.yale.edu/news-article...
#Medsky
Targeting the generation of variation may be the best route to personalized and durable treatments 🧪.
ysph.yale.edu/news-article...
#Medsky
Suppressing Key Enzymes Could Improve Lung Cancer Treatment Outcomes
Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some patients with non-small cell lung cancer
ysph.yale.edu
May 11, 2025 at 11:10 PM
Suppressing APOBEC enzymes—key drivers of tumor mutations—could dramatically delay drug resistance in non-small cell #lungcancer (#NSCLC), up to 1200%!
Targeting the generation of variation may be the best route to personalized and durable treatments 🧪.
ysph.yale.edu/news-article...
#Medsky
Targeting the generation of variation may be the best route to personalized and durable treatments 🧪.
ysph.yale.edu/news-article...
#Medsky
Reposted
Nuvalent Q1 EPS Misses as R&D Soars; Key Drug Milestones On Track https://signalbloom.ai/news/NUVL/nuvalent-q1-eps-misses-as-rd-soars-key-drug-milestones-on-track $NUVL #Earnings via @signalbloom.ai
May 8, 2025 at 11:43 AM
Nuvalent Q1 EPS Misses as R&D Soars; Key Drug Milestones On Track https://signalbloom.ai/news/NUVL/nuvalent-q1-eps-misses-as-rd-soars-key-drug-milestones-on-track $NUVL #Earnings via @signalbloom.ai